Coumarin-based inhibitors of human NAD(P)H: Quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity

Karen A. Nolan, He Zhao, Paul F. Faulder, A. David Frenkel, David J. Timson, David Siegel, David Ross, Terrence R. Burke, Ian J. Stratford, Richard A. Bryce

Research output: Contribution to journalArticlepeer-review

Abstract

The enzyme human NAD(P)H quinone oxidoreductase-1 (NQO1), which is overexpressed in several types of tumor cell, is considered a design target for cancer therapeutics. We identify new coumarin-based competitive inhibitors of NQO1, one of which is nanomolar. Using computational docking and molecular dynamics, we obtain insights into the structural basis of inhibition. Selected inhibitors were then assessed for off-target effects associated with dicoumarol and were found to have differing effects on superoxide formation and mitochondrial respiration. A comparison of NQO1 inhibition and off-target effects for dicoumarol and its derivatives suggests that the ability of dicoumarol to kill cancer cells is independent of NQO1 inhibition, that cellular superoxide production by dicoumarol does not seem linked to NQO1 inhibition but may be related to mitochondrial decoupling, and that superoxide does not appear to be a major determinant of cytotoxicity. Implications are discussed for NQO1 inhibition as an anticancer drug design target and superoxide generation as the dicoumarol-mediated mechanism of cytotoxicity.

Original languageEnglish
Pages (from-to)6316-6325
Number of pages10
JournalJournal of Medicinal Chemistry
Volume50
Issue number25
DOIs
Publication statusPublished - 15 Dec 2007

Fingerprint

Dive into the research topics of 'Coumarin-based inhibitors of human NAD(P)H: Quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity'. Together they form a unique fingerprint.

Cite this